Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lancaster, PA
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lancaster, PA
Click here to add this to my saved trials
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
East Providence, RI
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
East Providence, RI
Click here to add this to my saved trials
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Myrtle Beach, SC
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Salem, VA
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Salem, VA
Click here to add this to my saved trials
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Burien, WA
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Burien, WA
Click here to add this to my saved trials
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Seattle, WA
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tacoma, WA
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
mi
from
Calgary,
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Calgary,
Click here to add this to my saved trials
Oncology Episode Payment Model in Hawaii
Oncology Episode Payment Model in Hawaii
Status: Enrolling
Updated:  12/31/1969
Hawaii Oncology
mi
from
Honolulu, HI
Oncology Episode Payment Model in Hawaii
Oncology Episode Payment Model in Hawaii
Status: Enrolling
Updated: 12/31/1969
Hawaii Oncology
mi
from
Honolulu, HI
Click here to add this to my saved trials
Prospective Tumor Response Evaluation
Prospective Evaluation of Tumor Response to Cancer Treatment Therapies
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Prospective Tumor Response Evaluation
Prospective Evaluation of Tumor Response to Cancer Treatment Therapies
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer
A Phase 1 Dose-Escalation Study to Examine the Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Scottsdale, AZ
Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer
A Phase 1 Dose-Escalation Study to Examine the Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available
Phase I Study of Anti-Insulin-Like Growth Factor-I Receptor (IGF-IR) Monoclonal Antibody IMC-A12 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom No Standard Therapy is Available
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Scottsdale, AZ
A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available
Phase I Study of Anti-Insulin-Like Growth Factor-I Receptor (IGF-IR) Monoclonal Antibody IMC-A12 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom No Standard Therapy is Available
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available
Phase I Study of Anti-Insulin-Like Growth Factor-I Receptor (IGF-IR) Monoclonal Antibody IMC-A12 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom No Standard Therapy is Available
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Detroit, MI
A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available
Phase I Study of Anti-Insulin-Like Growth Factor-I Receptor (IGF-IR) Monoclonal Antibody IMC-A12 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom No Standard Therapy is Available
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available
Phase I Study of Anti-Insulin-Like Growth Factor-I Receptor (IGF-IR) Monoclonal Antibody IMC-A12 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom No Standard Therapy is Available
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Seattle, WA
A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available
Phase I Study of Anti-Insulin-Like Growth Factor-I Receptor (IGF-IR) Monoclonal Antibody IMC-A12 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom No Standard Therapy is Available
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Cognitive Remediation Therapy (CRT) for Adults Treated for Cancer
Cognitive Remediation Therapy (CRT) for Adults Treated for Cancer: A Single-arm Proof of Concept Study.
Status: Enrolling
Updated:  12/31/1969
VA Connecticut Healthcare System
mi
from
West Haven, CT
Cognitive Remediation Therapy (CRT) for Adults Treated for Cancer
Cognitive Remediation Therapy (CRT) for Adults Treated for Cancer: A Single-arm Proof of Concept Study.
Status: Enrolling
Updated: 12/31/1969
VA Connecticut Healthcare System
mi
from
West Haven, CT
Click here to add this to my saved trials
MRI With C13 Pilot Study Prostate Cancer
A Pilot Study to Evaluate the Reproducibility of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) and Its Ability to Reflect Treatment Effects in Patients With Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
MRI With C13 Pilot Study Prostate Cancer
A Pilot Study to Evaluate the Reproducibility of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) and Its Ability to Reflect Treatment Effects in Patients With Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Fenretinide in Treating Patients With Cervical Neoplasia
A Randomized Double-Blind Study of N-(4-hydroxyphenyl) Retinamide (4-HPR) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Fenretinide in Treating Patients With Cervical Neoplasia
A Randomized Double-Blind Study of N-(4-hydroxyphenyl) Retinamide (4-HPR) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Fatigue and Cancer Treatment(FACT)- an Exercise Intervention
Mitigating Cancer Treatment-Related Fatigue by Exercise
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University School of Nursing
mi
from
Baltimore, MD
Fatigue and Cancer Treatment(FACT)- an Exercise Intervention
Mitigating Cancer Treatment-Related Fatigue by Exercise
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University School of Nursing
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
A Phase II Study of Ixabepilone Prior to Surgery for High-risk Localized Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
A Phase II Study of Ixabepilone Prior to Surgery for High-risk Localized Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Irofulven in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of MGI-114 (NSC# 683863) Administered Intravenously for Five Days Every 28 Days to Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Irofulven in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of MGI-114 (NSC# 683863) Administered Intravenously for Five Days Every 28 Days to Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer
Phase II Study of Dolastatin 10 (NSC# 376128) Administered Intravenously Every 21 Days to Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer
Phase II Study of Dolastatin 10 (NSC# 376128) Administered Intravenously Every 21 Days to Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer
Phase II Study of Dolastatin 10 (NSC# 376128) Administered Intravenously Every 21 Days to Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer
Phase II Study of Dolastatin 10 (NSC# 376128) Administered Intravenously Every 21 Days to Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Radiation Therapy Plus Fludarabine in Treating Patients With Locally Advanced Cancer of the Mouth, Pharynx, or Larynx
A Phase I Study of Fludarabine With Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Radiation Therapy Plus Fludarabine in Treating Patients With Locally Advanced Cancer of the Mouth, Pharynx, or Larynx
A Phase I Study of Fludarabine With Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Study of Alpha-Difluromethylornithine (DFMO) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Study of Alpha-Difluromethylornithine (DFMO) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Birmingham Hematology and Oncology
mi
from
Birmingham, AL
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Birmingham Hematology and Oncology
mi
from
Birmingham, AL
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Asscociates
mi
from
Phoenix, AZ
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Asscociates
mi
from
Phoenix, AZ
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Northern AZ Hematology and Oncology Assoc
mi
from
Sedona, AZ
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Northern AZ Hematology and Oncology Assoc
mi
from
Sedona, AZ
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Center-Rose
mi
from
Denver, CO
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Center-Rose
mi
from
Denver, CO
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Northwestern Connecticut Oncology-Hematology Associates
mi
from
Torrington, CT
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Northwestern Connecticut Oncology-Hematology Associates
mi
from
Torrington, CT
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Melbourne Internal Medicine Associates
mi
from
Melbourne, FL
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Melbourne Internal Medicine Associates
mi
from
Melbourne, FL
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Institute
mi
from
New Port Richey, FL
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Institute
mi
from
New Port Richey, FL
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Ocala Oncology Center
mi
from
Ocala, FL
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Ocala Oncology Center
mi
from
Ocala, FL
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Centers of Florida
mi
from
Ocoee, FL
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Centers of Florida
mi
from
Ocoee, FL
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Hematology and Oncology Associates of IL
mi
from
Chicago, IL
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Hematology and Oncology Associates of IL
mi
from
Chicago, IL
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Central Indiana Cancer Center
mi
from
Indianapolis, IN
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Central Indiana Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Kansas City Cancer-Southwest
mi
from
Overland Park, KA
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Kansas City Cancer-Southwest
mi
from
Overland Park, KA
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Maryland Oncology Hematology PA
mi
from
Columbia, MD
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Maryland Oncology Hematology PA
mi
from
Columbia, MD
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Missouri Cancer Associates
mi
from
Columbia, MO
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Missouri Cancer Associates
mi
from
Columbia, MO
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Arch Medical Services
mi
from
Saint Louis, MO
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Arch Medical Services
mi
from
Saint Louis, MO
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
NH Oncology-Hematology, PA
mi
from
Hooksett, NH
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
NH Oncology-Hematology, PA
mi
from
Hooksett, NH
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Hematology-Oncology Associates of NNJ, PA
mi
from
Morristown, NJ
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Hematology-Oncology Associates of NNJ, PA
mi
from
Morristown, NJ
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Summit Medical Group
mi
from
Summit, NJ
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Summit Medical Group
mi
from
Summit, NJ
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
New York Oncology Hematology PC
mi
from
Albany, NY
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
New York Oncology Hematology PC
mi
from
Albany, NY
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
New York Oncology Hematology, PC
mi
from
Rexford, NY
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
New York Oncology Hematology, PC
mi
from
Rexford, NY
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Interlakes Oncology/Hematology PC
mi
from
Rochester, NY
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Interlakes Oncology/Hematology PC
mi
from
Rochester, NY
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Raleigh Hematology Oncology Clinic
mi
from
Cary, NC
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Raleigh Hematology Oncology Clinic
mi
from
Cary, NC
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Greater Dayton Cancer Center
mi
from
Kettering, OH
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Greater Dayton Cancer Center
mi
from
Kettering, OH
Click here to add this to my saved trials